Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics (SIX:RLF, OTCQB:RLFTY) has announced the sale of its GOLIKE intellectual property and commercialization rights outside the United States to Nutrisens for CHF 1.2 million upfront, plus potential contingent payments. This transaction marks the completion of Relief's strategic transition from direct marketing to a partnership-based model.
Under the agreement, Nutrisens will manage GOLIKE's marketing and sales in European markets and take over existing third-party distribution agreements in other regions. Relief maintains U.S. rights, where GOLIKE is exclusively licensed to Eton Pharmaceuticals, and will continue global supply and development of line extensions.
Following the transaction, Relief reported a cash balance of CHF 15.3 million as of January 22, 2025. The company will focus on advancing its R&D programs in rare dermatology and metabolic disorders, while exploring potential expansion into gastrointestinal therapeutics through ongoing discussions with Renexxion.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTY) ha annunciato la vendita dei diritti di proprietà intellettuale e di commercializzazione del suo prodotto GOLIKE al di fuori degli Stati Uniti a Nutrisens per CHF 1,2 milioni in anticipo, oltre a potenziali pagamenti variabili. Questa transazione segna il completamento della transizione strategica di Relief da un modello di marketing diretto a uno basato su partnership.
Secondo l'accordo, Nutrisens gestirà il marketing e le vendite di GOLIKE nei mercati europei e si occuperà degli attuali accordi di distribuzione di terzi in altre regioni. Relief mantiene i diritti negli Stati Uniti, dove GOLIKE è concesso in licenza esclusiva a Eton Pharmaceuticals, e continuerà a fornire e sviluppare globalmente estensioni della linea.
Dopo la transazione, Relief ha riportato un saldo di cassa di CHF 15,3 milioni al 22 gennaio 2025. L'azienda si concentrerà sul progresso dei suoi programmi di R&D in dermatologia rare e disturbi metabolici, mentre esplora potenziali espansioni in ambito terapeutico gastrointestinale attraverso discussioni in corso con Renexxion.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTY) ha anunciado la venta de sus derechos de propiedad intelectual y comercialización de GOLIKE fuera de los Estados Unidos a Nutrisens por CHF 1,2 millones por adelantado, más pagos contingentes potenciales. Esta transacción marca la finalización de la transición estratégica de Relief de un modelo de mercadeo directo a uno basado en asociaciones.
Según el acuerdo, Nutrisens gestionará el marketing y las ventas de GOLIKE en los mercados europeos y se hará cargo de los acuerdos de distribución existentes de terceros en otras regiones. Relief mantiene los derechos en EE.UU., donde GOLIKE está licenciado exclusivamente a Eton Pharmaceuticals, y continuará suministrando y desarrollando globalmente extensiones de la línea.
Tras la transacción, Relief reportó un saldo en efectivo de CHF 15,3 millones a partir del 22 de enero de 2025. La compañía se centrará en avanzar sus programas de I+D en dermatología rara y trastornos metabólicos, mientras explora una posible expansión en terapias gastrointestinales a través de discusiones en curso con Renexxion.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTY)는 GOLIKE의 지적 재산권 및 상업화 권리를 미국 외부에서 Nutrisens에 CHF 120만에 판매한다고 발표했습니다. 이 거래는 Relief가 직접 마케팅 모델에서 파트너십 기반 모델로 전략적 전환을 완료했음을 의미합니다.
계약에 따라 Nutrisens는 유럽 시장에서 GOLIKE의 마케팅 및 판매를 관리하고 다른 지역의 기존 제3자 유통 계약을 인수하게 됩니다. Relief는 미국 내에서 GOLIKE의 독점 라이센스를 Eton Pharmaceuticals에 부여하고 있으며, 글로벌 공급 및 라인 확장의 개발을 계속합니다.
거래 후, Relief는 2025년 1월 22일 기준으로 CHF 1530만의 현금 잔액을 보고했습니다. 이 회사는 희귀 피부 질환 및 대사 장애에 대한 연구개발 프로그램을 발전시키는 데 집중하고 있으며, Renexxion과의 지속적인 논의를 통해 위장 치료제로의 확장 가능성을 탐색하고 있습니다.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTY) a annoncé la vente de ses droits de propriété intellectuelle et de commercialisation pour GOLIKE en dehors des États-Unis à Nutrisens pour CHF 1,2 million d'avance, ainsi que des paiements contingents potentiels. Cette transaction marque l'achèvement de la transition stratégique de Relief d'un modèle de marketing direct à un modèle basé sur le partenariat.
Conformément à l'accord, Nutrisens gérera le marketing et les ventes de GOLIKE sur les marchés européens et prendra en charge les accords de distribution existants de tiers dans d'autres régions. Relief conserve les droits aux États-Unis, où GOLIKE est sous licence exclusive à Eton Pharmaceuticals, et continuera à fournir et à développer globalement des extensions de la ligne.
Suite à la transaction, Relief a déclaré un solde de trésorerie de CHF 15,3 millions au 22 janvier 2025. L'entreprise se concentrera sur l'avancement de ses programmes de R&D dans les domaines de la dermatologie rare et des troubles métaboliques, tout en explorant une expansion potentielle vers des thérapeutiques gastro-intestinales à travers des discussions en cours avec Renexxion.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTY) hat den Verkauf seiner geistigen Eigentums- und Verwertungsrechte für GOLIKE außerhalb der Vereinigten Staaten an Nutrisens für CHF 1,2 Millionen im Voraus sowie potenzielle bedingte Zahlungen angekündigt. Diese Transaktion markiert den Abschluss der strategischen Umstellung von Relief von einem Direktvertriebsmodell auf ein partnerschaftliches Modell.
Gemäß der Vereinbarung wird Nutrisens das Marketing und die Verkäufe von GOLIKE in den europäischen Märkten verwalten und bestehende Drittvertriebsvereinbarungen in anderen Regionen übernehmen. Relief behält die Rechte in den USA, wo GOLIKE exklusiv an Eton Pharmaceuticals lizenziert ist, und wird weiterhin die globale Versorgung und Entwicklung von Produktlinien-Erweiterungen fortsetzen.
Nach der Transaktion meldete Relief einen Kassenbestand von CHF 15,3 Millionen zum 22. Januar 2025. Das Unternehmen wird sich auf die Weiterentwicklung seiner F&E-Programme in den Bereichen seltene Dermatologie und Stoffwechselerkrankungen konzentrieren und gleichzeitig potenzielle Expansionen in den Bereich der gastrointestinalen Therapeutika durch laufende Gespräche mit Renexxion untersuchen.
- Received CHF 1.2 million upfront payment with additional contingent payments possible
- Maintains strong cash position of CHF 15.3 million as of January 22, 2025
- Cost structure optimization through transition to partnership-based model
- Retains U.S. rights for GOLIKE
- Divestment of GOLIKE rights in international markets reduces direct market presence
- Increased dependency on partners for product commercialization
Sale of GOLIKE® Rights Outside the U.S. to Nutrisens
Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products
GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the sale of its intellectual property and commercialization rights for GOLIKE outside the United States to Nutrisens, a leading independent platform that develops and commercializes clinical nutrition solutions for patients. This transaction completes Relief's previously announced transition from a direct marketing and sales infrastructure to a partnership-based model, enabling the Company to optimize its cost structure and allocate resources on advancing its high-priority R&D programs.
Under the agreement, Nutrisens will take over marketing and sales activities for GOLIKE in Relief's European markets. Relief has also transferred its existing third-party distribution agreements for GOLIKE in other regions to Nutrisens, while retaining its rights in the United States, where the product is exclusively licensed to Eton Pharmaceuticals. With its significant experience, Nutrisens will continue to support patients and health professionals with GOLIKE solutions worldwide outside the United States. Relief intends to continue to supply GOLIKE globally and complete development of certain line extensions to address patient needs.
"Throughout the past year, we have progressively transformed our organization to build on our strengths in drug development and the business-to-business commercialization of our products," said Dr. Raghuram Selvaraju, chairman of Relief's board of directors. "This strategic transformation has refocused our efforts on developing innovative treatments, streamlined operations, and enhanced our ability to serve patients. We are well-positioned to continue advancing our programs in rare dermatology and metabolic disorders, while in parallel, we continue to explore a potential pipeline expansion into the gastrointestinal therapeutic space through our ongoing discussions with Renexxion."
Relief received CHF 1.2 million upfront from Nutrisens and is eligible for certain contingent payments. Following this payment, Relief reported a cash balance of CHF 15.3 million as of January 22, 2025, ensuring its capacity to achieve key near-term R&D milestones and advance its strategic objectives.
ABOUT GOLIKE®
GOLIKE products are Foods for Special Medical Purposes (FSMPs) developed by Relief with prolonged-release formulations that closely replicate the physiological absorption of amino acids found in natural proteins. By masking the unpleasant taste and odor typically associated with amino acids, GOLIKE offers a more palatable and patient-friendly solution addressing key challenges in dietary management. The GOLIKE product line includes PKU GOLIKE, designed for the dietary management of phenylketonuria, as well as additional products currently in development.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
How much did Relief Therapeutics (RLFTY) receive for selling GOLIKE rights outside the US?
What is Relief Therapeutics' (RLFTY) cash position as of January 22, 2025?
Who will market GOLIKE in European markets after Relief's (RLFTY) sale?
What therapeutic areas will Relief Therapeutics (RLFTY) focus on after the GOLIKE sale?
Who holds the U.S. rights for GOLIKE after Relief's (RLFTY) sale to Nutrisens?
